Drug Information

Drug General Information
Drug ID
D0V4RZ
Former ID
DNC008995
Drug Name
WAY-214950
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529781]
Formula
C21H13F5N2
Canonical SMILES
C1=CC=C(C(=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=C(C=C<br />4)F)F
InChI
1S/C21H13F5N2/c22-15-10-8-13(9-11-15)20-16-5-3-6-17(21(24,25)26)19(16)27-28(20)12-14-4-1-2-7-18(14)23/h1-11H,12H2
InChIKey
NHSFDMDEDPAKNH-UHFFFAOYSA-N
PubChem Compound ID
25113722
Target and Pathway
Target(s) Oxysterols receptor LXR-beta Target Info Inhibitor [529781]
Pregnane X receptor Target Info Inhibitor [529781]
Oxysterols receptor LXR-alpha Target Info Inhibitor [529781]
mRNA of glucocorticoid receptor Target Info Inhibitor [529781]
KEGG Pathway PPAR signaling pathway
Non-alcoholic fatty liver disease (NAFLD)
Hepatitis Chsa04080:Neuroactive ligand-receptor interaction
NetPath Pathway IL2 Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptorsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by HDAC Class II
FOXA2 and FOXA3 transcription factor networks
Glucocorticoid receptor regulatory network
Regulation of Androgen receptor activity
AP-1 transcription factor network
Reactome Nuclear Receptor transcription pathwayR-HSA-1368108:BMAL1:CLOCK,NPAS2 activates circadian gene expression
WikiPathways SREBP signalling
Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity
Nuclear Receptors Meta-Pathway
Pregnane X Receptor pathway
Drug Induction of Bile Acid Pathway
PPAR Alpha Pathway
Liver X Receptor Pathway
Adipogenesis
SREBF and miR33 in cholesterol and lipid homeostasis
Nuclear ReceptorsWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
SIDS Susceptibility Pathways
Endoderm Differentiation
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Circadian Clock
Nuclear Receptors
References
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.